Shkreli's KaloBios buys Chagas disease drug rights, shares soar

(Reuters) - KaloBios Pharmaceuticals Inc, which recently appointed controversial head of Turing Pharmaceuticals Martin Shkreli as CEO, said it was acquiring worldwide rights to a compound being developed for the treatment of Chagas disease.

Source: Reuters: Health - December 3, 2015 Category: Consumer Health News Tags: healthNews Source Type: news